APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cellular Tumor Antigen p53

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cellular Tumor Antigen p53 Market Analysis and Forecast 2026-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchCellular Tumor Antigen p53 Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Cellular Tumor Antigen p53 Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Cellular Tumor Antigen p53 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cellular Tumor Antigen p53 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cellular Tumor Antigen p53 Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cellular Tumor Antigen p53 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cellular Tumor Antigen p53 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cellular Tumor Antigen p53 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cellular Tumor Antigen p53 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cellular Tumor Antigen p53 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cellular Tumor Antigen p53 include Z53 Therapeutics, LLC, Tara Immuno-Oncology Therapeutics LLC, Stemline Therapeutics, Inc., SK Biopharmaceuticals Co., Ltd., Shenzen SiBiono GeneTech Co., Ltd., Quark Pharmaceuticals, Inc., PCI Biotech Holding ASA, OSE Pharma SA and ORCA Therapeutics B.V., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cellular Tumor Antigen p53, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cellular Tumor Antigen p53, also provides the sales of main regions and countries. Of the upcoming market potential for Cellular Tumor Antigen p53, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cellular Tumor Antigen p53 sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cellular Tumor Antigen p53 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cellular Tumor Antigen p53 sales, projected growth trends, production technology, application and end-user industry.

Cellular Tumor Antigen p53 Segment by Company

Z53 Therapeutics, LLC

Tara Immuno-Oncology Therapeutics LLC

Stemline Therapeutics, Inc.

SK Biopharmaceuticals Co., Ltd.

Shenzen SiBiono GeneTech Co., Ltd.

Quark Pharmaceuticals, Inc.

PCI Biotech Holding ASA

OSE Pharma SA

ORCA Therapeutics B.V.

Eleos Inc.

Critical Outcome Technologies Inc.

Cellceutix Corporation

Aprea AB

American Gene Technologies International Inc.

Advaxis, Inc.

Cellular Tumor Antigen p53 Segment by Type

APR-246

ATRN-502

COTI-2

D-12PGJ3

MJ-05

MX-225

Cenersen Sodium

Others

Cellular Tumor Antigen p53 Segment by Application

Prostate Cancer

Brain Cancer

Ovarian Cancer

Others

Cellular Tumor Antigen p53 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cellular Tumor Antigen p53 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cellular Tumor Antigen p53 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cellular Tumor Antigen p53.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cellular Tumor Antigen p53 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cellular Tumor Antigen p53 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cellular Tumor Antigen p53 sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cellular Tumor Antigen p53 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. APR-246 Major Manufacturers Table 3. ATRN-502 Major Manufacturers Table 4. COTI-2 Major Manufacturers Table 5. D-12PGJ3 Major Manufacturers Table 6. MJ-05 Major Manufacturers Table 7. MX-225 Major Manufacturers Table 8. Cenersen Sodium Major Manufacturers Table 9. Others Major Manufacturers Table 10. Global Cellular Tumor Antigen p53 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. Prostate Cancer Major Manufacturers Table 12. Brain Cancer Major Manufacturers Table 13. Ovarian Cancer Major Manufacturers Table 14. Others Major Manufacturers Table 15. Cellular Tumor Antigen p53 Industry Trends Table 16. Cellular Tumor Antigen p53 Industry Drivers Table 17. Cellular Tumor Antigen p53 Industry Opportunities and Challenges Table 18. Cellular Tumor Antigen p53 Industry Restraints Table 19. Global Cellular Tumor Antigen p53 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Cellular Tumor Antigen p53 Revenue by Region (2021-2026) & (US$ Million) Table 21. Global Cellular Tumor Antigen p53 Revenue by Region (2027-2032) & (US$ Million) Table 22. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2021-2026) Table 23. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2027-2032) Table 24. Global Cellular Tumor Antigen p53 Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 25. Global Cellular Tumor Antigen p53 Sales by Region (2021-2026) & (W Units) Table 26. Global Cellular Tumor Antigen p53 Sales by Region (2027-2032) & (W Units) Table 27. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2021-2026) Table 28. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2027-2032) Table 29. Global Cellular Tumor Antigen p53 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Cellular Tumor Antigen p53 Revenue Market Share by Manufacturers (2021-2026) Table 31. Global Cellular Tumor Antigen p53 Sales by Manufacturers (US$ Million) & (2021-2026) Table 32. Global Cellular Tumor Antigen p53 Sales Market Share by Manufacturers (2021-2026) Table 33. Global Cellular Tumor Antigen p53 Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 34. Global Cellular Tumor Antigen p53 Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 35. Global Cellular Tumor Antigen p53 Key Manufacturers Manufacturing Sites & Headquarters Table 36. Global Cellular Tumor Antigen p53 Manufacturers, Product Type & Application Table 37. Global Cellular Tumor Antigen p53 Manufacturers' Establishment Date Table 38. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 39. Global Cellular Tumor Antigen p53 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Cellular Tumor Antigen p53 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 42. Global Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 43. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2026) Table 44. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2027-2032) Table 45. Global Cellular Tumor Antigen p53 Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 46. Global Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 47. Global Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 48. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2026) Table 49. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2027-2032) Table 50. Global Cellular Tumor Antigen p53 Price by Type (2021-2026) & (US$/Unit) Table 51. Global Cellular Tumor Antigen p53 Price by Type (2027-2032) & (US$/Unit) Table 52. Global Cellular Tumor Antigen p53 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 54. Global Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 55. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2026) Table 56. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2027-2032) Table 57. Global Cellular Tumor Antigen p53 Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 58. Global Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 59. Global Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 60. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2026) Table 61. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2027-2032) Table 62. Global Cellular Tumor Antigen p53 Price by Application (2021-2026) & (US$/Unit) Table 63. Global Cellular Tumor Antigen p53 Price by Application (2027-2032) & (US$/Unit) Table 64. Z53 Therapeutics, LLC Company Information Table 65. Z53 Therapeutics, LLC Business Overview Table 66. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio Table 68. Z53 Therapeutics, LLC Recent Development Table 69. Tara Immuno-Oncology Therapeutics LLC Company Information Table 70. Tara Immuno-Oncology Therapeutics LLC Business Overview Table 71. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio Table 73. Tara Immuno-Oncology Therapeutics LLC Recent Development Table 74. Stemline Therapeutics, Inc. Company Information Table 75. Stemline Therapeutics, Inc. Business Overview Table 76. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 78. Stemline Therapeutics, Inc. Recent Development Table 79. SK Biopharmaceuticals Co., Ltd. Company Information Table 80. SK Biopharmaceuticals Co., Ltd. Business Overview Table 81. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio Table 83. SK Biopharmaceuticals Co., Ltd. Recent Development Table 84. Shenzen SiBiono GeneTech Co., Ltd. Company Information Table 85. Shenzen SiBiono GeneTech Co., Ltd. Business Overview Table 86. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio Table 88. Shenzen SiBiono GeneTech Co., Ltd. Recent Development Table 89. Quark Pharmaceuticals, Inc. Company Information Table 90. Quark Pharmaceuticals, Inc. Business Overview Table 91. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 93. Quark Pharmaceuticals, Inc. Recent Development Table 94. PCI Biotech Holding ASA Company Information Table 95. PCI Biotech Holding ASA Business Overview Table 96. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio Table 98. PCI Biotech Holding ASA Recent Development Table 99. OSE Pharma SA Company Information Table 100. OSE Pharma SA Business Overview Table 101. OSE Pharma SA Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio Table 103. OSE Pharma SA Recent Development Table 104. ORCA Therapeutics B.V. Company Information Table 105. ORCA Therapeutics B.V. Business Overview Table 106. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio Table 108. ORCA Therapeutics B.V. Recent Development Table 109. Eleos Inc. Company Information Table 110. Eleos Inc. Business Overview Table 111. Eleos Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio Table 113. Eleos Inc. Recent Development Table 114. Critical Outcome Technologies Inc. Company Information Table 115. Critical Outcome Technologies Inc. Business Overview Table 116. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio Table 118. Critical Outcome Technologies Inc. Recent Development Table 119. Cellceutix Corporation Company Information Table 120. Cellceutix Corporation Business Overview Table 121. Cellceutix Corporation Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio Table 123. Cellceutix Corporation Recent Development Table 124. Aprea AB Company Information Table 125. Aprea AB Business Overview Table 126. Aprea AB Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Aprea AB Cellular Tumor Antigen p53 Product Portfolio Table 128. Aprea AB Recent Development Table 129. American Gene Technologies International Inc. Company Information Table 130. American Gene Technologies International Inc. Business Overview Table 131. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio Table 133. American Gene Technologies International Inc. Recent Development Table 134. Advaxis, Inc. Company Information Table 135. Advaxis, Inc. Business Overview Table 136. Advaxis, Inc. Cellular Tumor Antigen p53 Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio Table 138. Advaxis, Inc. Recent Development Table 139. North America Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 140. North America Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 141. North America Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 142. North America Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 143. North America Cellular Tumor Antigen p53 Sales Price by Type (2021-2026) & (US$/Unit) Table 144. North America Cellular Tumor Antigen p53 Sales Price by Type (2027-2032) & (US$/Unit) Table 145. North America Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 146. North America Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 147. North America Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 148. North America Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 149. North America Cellular Tumor Antigen p53 Sales Price by Application (2021-2026) & (US$/Unit) Table 150. North America Cellular Tumor Antigen p53 Sales Price by Application (2027-2032) & (US$/Unit) Table 151. North America Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. North America Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. North America Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. North America Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 155. North America Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 156. North America Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 157. North America Cellular Tumor Antigen p53 Sales Price by Country (2021-2026) & (US$/Unit) Table 158. North America Cellular Tumor Antigen p53 Sales Price by Country (2027-2032) & (US$/Unit) Table 159. United States Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 160. Canada Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 161. Mexico Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 162. Europe Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 163. Europe Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 164. Europe Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 165. Europe Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 166. Europe Cellular Tumor Antigen p53 Sales Price by Type (2021-2026) & (US$/Unit) Table 167. Europe Cellular Tumor Antigen p53 Sales Price by Type (2027-2032) & (US$/Unit) Table 168. Europe Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 169. Europe Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 170. Europe Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 171. Europe Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 172. Europe Cellular Tumor Antigen p53 Sales Price by Application (2021-2026) & (US$/Unit) Table 173. Europe Cellular Tumor Antigen p53 Sales Price by Application (2027-2032) & (US$/Unit) Table 174. Europe Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Europe Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. Europe Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. Europe Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 178. Europe Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 179. Europe Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 180. Europe Cellular Tumor Antigen p53 Sales Price by Country (2021-2026) & (US$/Unit) Table 181. Europe Cellular Tumor Antigen p53 Sales Price by Country (2027-2032) & (US$/Unit) Table 182. Germany Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 183. France Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 184. U.K. Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 185. Italy Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 186. Russia Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 187. Spain Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 188. Netherlands Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 189. Switzerland Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 190. Sweden Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 191. Poland Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 192. China Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 193. China Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 194. China Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 195. China Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 196. China Cellular Tumor Antigen p53 Sales Price by Type (2021-2026) & (US$/Unit) Table 197. China Cellular Tumor Antigen p53 Sales Price by Type (2027-2032) & (US$/Unit) Table 198. China Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 199. China Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 200. China Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 201. China Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 202. China Cellular Tumor Antigen p53 Sales Price by Application (2021-2026) & (US$/Unit) Table 203. China Cellular Tumor Antigen p53 Sales Price by Application (2027-2032) & (US$/Unit) Table 204. Asia Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 205. Asia Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 206. Asia Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 207. Asia Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 208. Asia Cellular Tumor Antigen p53 Sales Price by Type (2021-2026) & (US$/Unit) Table 209. Asia Cellular Tumor Antigen p53 Sales Price by Type (2027-2032) & (US$/Unit) Table 210. Asia Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 211. Asia Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 212. Asia Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 213. Asia Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 214. Asia Cellular Tumor Antigen p53 Sales Price by Application (2021-2026) & (US$/Unit) Table 215. Asia Cellular Tumor Antigen p53 Sales Price by Application (2027-2032) & (US$/Unit) Table 216. Asia Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. Asia Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. Asia Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. Asia Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 220. Asia Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 221. Asia Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 222. Asia Cellular Tumor Antigen p53 Sales Price by Country (2021-2026) & (US$/Unit) Table 223. Asia Cellular Tumor Antigen p53 Sales Price by Country (2027-2032) & (US$/Unit) Table 224. Japan Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 225. South Korea Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 226. India Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 227. Australia Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 228. Taiwan Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 229. Southeast Asia Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 230. SAMEA Cellular Tumor Antigen p53 Revenue by Type (2021-2026) & (US$ Million) Table 231. SAMEA Cellular Tumor Antigen p53 Revenue by Type (2027-2032) & (US$ Million) Table 232. SAMEA Cellular Tumor Antigen p53 Sales by Type (2021-2026) & (W Units) Table 233. SAMEA Cellular Tumor Antigen p53 Sales by Type (2027-2032) & (W Units) Table 234. SAMEA Cellular Tumor Antigen p53 Sales Price by Type (2021-2026) & (US$/Unit) Table 235. SAMEA Cellular Tumor Antigen p53 Sales Price by Type (2027-2032) & (US$/Unit) Table 236. SAMEA Cellular Tumor Antigen p53 Revenue by Application (2021-2026) & (US$ Million) Table 237. SAMEA Cellular Tumor Antigen p53 Revenue by Application (2027-2032) & (US$ Million) Table 238. SAMEA Cellular Tumor Antigen p53 Sales by Application (2021-2026) & (W Units) Table 239. SAMEA Cellular Tumor Antigen p53 Sales by Application (2027-2032) & (W Units) Table 240. SAMEA Cellular Tumor Antigen p53 Sales Price by Application (2021-2026) & (US$/Unit) Table 241. SAMEA Cellular Tumor Antigen p53 Sales Price by Application (2027-2032) & (US$/Unit) Table 242. SAMEA Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. SAMEA Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. SAMEA Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. SAMEA Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 246. SAMEA Cellular Tumor Antigen p53 Sales by Country (2021-2026) & (W Units) Table 247. SAMEA Cellular Tumor Antigen p53 Sales by Country (2027-2032) & (W Units) Table 248. SAMEA Cellular Tumor Antigen p53 Sales Price by Country (2021-2026) & (US$/Unit) Table 249. SAMEA Cellular Tumor Antigen p53 Sales Price by Country (2027-2032) & (US$/Unit) Table 250. Brazil Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 251. Argentina Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 252. Chile Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 253. Colombia Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 254. Peru Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 255. Saudi Arabia Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 256. Israel Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 257. UAE Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 258. Turkey Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 259. Iran Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 260. Egypt Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Table 261. Key Raw Materials Table 262. Raw Materials Key Suppliers Table 263. Cellular Tumor Antigen p53 Distributors List Table 264. Cellular Tumor Antigen p53 Customers List Table 265. Research Programs/Design for This Report Table 266. Authors List of This Report Table 267. Secondary Sources Table 268. Primary Sources List of Figures Figure 1. Cellular Tumor Antigen p53 Image Figure 2. Global Cellular Tumor Antigen p53 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cellular Tumor Antigen p53 Market Size Share 2021 VS 2025 VS 2032 Figure 4. APR-246 Image Figure 5. ATRN-502 Image Figure 6. COTI-2 Image Figure 7. D-12PGJ3 Image Figure 8. MJ-05 Image Figure 9. MX-225 Image Figure 10. Cenersen Sodium Image Figure 11. Others Image Figure 12. Global Cellular Tumor Antigen p53 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Cellular Tumor Antigen p53 Market Size Share 2021 VS 2025 VS 2032 Figure 14. Prostate Cancer Image Figure 15. Brain Cancer Image Figure 16. Ovarian Cancer Image Figure 17. Others Image Figure 18. Global Cellular Tumor Antigen p53 Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Cellular Tumor Antigen p53 Revenue (2021-2032) & (US$ Million) Figure 20. Global Cellular Tumor Antigen p53 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Cellular Tumor Antigen p53 Revenue Market Share by Region: 2025 Versus 2032 Figure 22. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2021-2032) Figure 23. Global Cellular Tumor Antigen p53 Sales (2021-2032) & (W Units) Figure 24. Global Cellular Tumor Antigen p53 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 25. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2021-2032) Figure 26. US & Canada & Mexico Cellular Tumor Antigen p53 Sales YoY (2021-2032) & (W Units) Figure 27. Europe Cellular Tumor Antigen p53 Sales YoY (2021-2032) & (W Units) Figure 28. China Cellular Tumor Antigen p53 Sales YoY (2021-2032) & (W Units) Figure 29. Asia (Excluding China) Cellular Tumor Antigen p53 Sales YoY (2021-2032) & (W Units) Figure 30. South America, Middle East and Africa Cellular Tumor Antigen p53 Sales YoY (2021-2032) & (W Units) Figure 31. Global Cellular Tumor Antigen p53 Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 32. Global Cellular Tumor Antigen p53 Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 33. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 34. Global Cellular Tumor Antigen p53 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Cellular Tumor Antigen p53 Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2032) Figure 37. Global Cellular Tumor Antigen p53 Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 38. Global Cellular Tumor Antigen p53 Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 39. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2032) Figure 40. Global Cellular Tumor Antigen p53 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 41. Global Cellular Tumor Antigen p53 Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2032) Figure 43. Global Cellular Tumor Antigen p53 Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 44. Global Cellular Tumor Antigen p53 Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 45. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2032) Figure 46. North America Cellular Tumor Antigen p53 Revenue Share by Type (2021-2032) Figure 47. North America Cellular Tumor Antigen p53 Sales Share by Type (2021-2032) Figure 48. North America Cellular Tumor Antigen p53 Revenue Share by Application (2021-2032) Figure 49. North America Cellular Tumor Antigen p53 Sales Share by Application (2021-2032) Figure 50. North America Cellular Tumor Antigen p53 Revenue Share by Country (2021-2032) Figure 51. North America Cellular Tumor Antigen p53 Sales Share by Country (2021-2032) Figure 52. Europe Cellular Tumor Antigen p53 Revenue Share by Type (2021-2032) Figure 53. Europe Cellular Tumor Antigen p53 Sales Share by Type (2021-2032) Figure 54. Europe Cellular Tumor Antigen p53 Revenue Share by Application (2021-2032) Figure 55. Europe Cellular Tumor Antigen p53 Sales Share by Application (2021-2032) Figure 56. Europe Cellular Tumor Antigen p53 Revenue Share by Country (2021-2032) Figure 57. Europe Cellular Tumor Antigen p53 Sales Share by Country (2021-2032) Figure 58. China Cellular Tumor Antigen p53 Revenue Share by Type (2021-2032) Figure 59. China Cellular Tumor Antigen p53 Sales Share by Type (2021-2032) Figure 60. China Cellular Tumor Antigen p53 Revenue Share by Application (2021-2032) Figure 61. China Cellular Tumor Antigen p53 Sales Share by Application (2021-2032) Figure 62. Asia Cellular Tumor Antigen p53 Revenue Share by Type (2021-2032) Figure 63. Asia Cellular Tumor Antigen p53 Sales Share by Type (2021-2032) Figure 64. Asia Cellular Tumor Antigen p53 Revenue Share by Application (2021-2032) Figure 65. Asia Cellular Tumor Antigen p53 Sales Share by Application (2021-2032) Figure 66. Asia Cellular Tumor Antigen p53 Revenue Share by Country (2021-2032) Figure 67. Asia Cellular Tumor Antigen p53 Sales Share by Country (2021-2032) Figure 68. SAMEA Cellular Tumor Antigen p53 Revenue Share by Type (2021-2032) Figure 69. SAMEA Cellular Tumor Antigen p53 Sales Share by Type (2021-2032) Figure 70. SAMEA Cellular Tumor Antigen p53 Revenue Share by Application (2021-2032) Figure 71. SAMEA Cellular Tumor Antigen p53 Sales Share by Application (2021-2032) Figure 72. SAMEA Cellular Tumor Antigen p53 Revenue Share by Country (2021-2032) Figure 73. SAMEA Cellular Tumor Antigen p53 Sales Share by Country (2021-2032) Figure 74. Cellular Tumor Antigen p53 Value Chain Figure 75. Manufacturing Cost Structure Figure 76. Cellular Tumor Antigen p53 Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • APR-246
  • ATRN-502
  • COTI-2
  • D-12PGJ3
  • MJ-05
  • MX-225
  • Cenersen Sodium
  • Others
Applications
  • Prostate Cancer
  • Brain Cancer
  • Ovarian Cancer
  • Others
Companies covered
  • Z53 Therapeutics, LLC
  • Tara Immuno-Oncology Therapeutics LLC
  • Stemline Therapeutics, Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Quark Pharmaceuticals, Inc.
  • PCI Biotech Holding ASA
  • OSE Pharma SA
  • ORCA Therapeutics B.V.
  • Eleos Inc.
  • Critical Outcome Technologies Inc.
  • Cellceutix Corporation
  • Aprea AB
  • American Gene Technologies International Inc.
  • Advaxis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cellular Tumor Antigen p53 Market by Type
  3. 1.2.1 Global Cellular Tumor Antigen p53 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 APR-246
  5. 1.2.3 ATRN-502
  6. 1.2.4 COTI-2
  7. 1.2.5 D-12PGJ3
  8. 1.2.6 MJ-05
  9. 1.2.7 MX-225
  10. 1.2.8 Cenersen Sodium
  11. 1.2.9 Others
  12. 1.3 Cellular Tumor Antigen p53 Market by Application
  13. 1.3.1 Global Cellular Tumor Antigen p53 Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 Prostate Cancer
  15. 1.3.3 Brain Cancer
  16. 1.3.4 Ovarian Cancer
  17. 1.3.5 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Cellular Tumor Antigen p53 Market Dynamics
  1. 2.1 Cellular Tumor Antigen p53 Industry Trends
  2. 2.2 Cellular Tumor Antigen p53 Industry Drivers
  3. 2.3 Cellular Tumor Antigen p53 Industry Opportunities and Challenges
  4. 2.4 Cellular Tumor Antigen p53 Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cellular Tumor Antigen p53 Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cellular Tumor Antigen p53 Revenue by Region
  3. 3.2.1 Global Cellular Tumor Antigen p53 Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cellular Tumor Antigen p53 Revenue by Region (2021-2026)
  5. 3.2.3 Global Cellular Tumor Antigen p53 Revenue by Region (2027-2032)
  6. 3.2.4 Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cellular Tumor Antigen p53 Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cellular Tumor Antigen p53 Sales by Region
  9. 3.4.1 Global Cellular Tumor Antigen p53 Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cellular Tumor Antigen p53 Sales by Region (2021-2026)
  11. 3.4.3 Global Cellular Tumor Antigen p53 Sales by Region (2027-2032)
  12. 3.4.4 Global Cellular Tumor Antigen p53 Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cellular Tumor Antigen p53 Revenue by Manufacturers
  2. 4.1.1 Global Cellular Tumor Antigen p53 Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cellular Tumor Antigen p53 Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cellular Tumor Antigen p53 Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cellular Tumor Antigen p53 Sales by Manufacturers
  6. 4.2.1 Global Cellular Tumor Antigen p53 Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cellular Tumor Antigen p53 Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cellular Tumor Antigen p53 Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cellular Tumor Antigen p53 Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cellular Tumor Antigen p53 Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cellular Tumor Antigen p53 Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cellular Tumor Antigen p53 Manufacturers, Product Type & Application
  13. 4.7 Global Cellular Tumor Antigen p53 Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cellular Tumor Antigen p53 Market CR5 and HHI
  16. 4.8.2 2025 Cellular Tumor Antigen p53 Tier 1, Tier 2, and Tier 3
5 Cellular Tumor Antigen p53 Market by Type
  1. 5.1 Global Cellular Tumor Antigen p53 Revenue by Type
  2. 5.1.1 Global Cellular Tumor Antigen p53 Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cellular Tumor Antigen p53 Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cellular Tumor Antigen p53 Sales by Type
  6. 5.2.1 Global Cellular Tumor Antigen p53 Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cellular Tumor Antigen p53 Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cellular Tumor Antigen p53 Price by Type
6 Cellular Tumor Antigen p53 Market by Application
  1. 6.1 Global Cellular Tumor Antigen p53 Revenue by Application
  2. 6.1.1 Global Cellular Tumor Antigen p53 Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cellular Tumor Antigen p53 Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cellular Tumor Antigen p53 Sales by Application
  6. 6.2.1 Global Cellular Tumor Antigen p53 Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cellular Tumor Antigen p53 Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cellular Tumor Antigen p53 Price by Application
7 Company Profiles
  1. 7.1 Z53 Therapeutics, LLC
  2. 7.1.1 Z53 Therapeutics, LLC Company Information
  3. 7.1.2 Z53 Therapeutics, LLC Business Overview
  4. 7.1.3 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio
  6. 7.1.5 Z53 Therapeutics, LLC Recent Developments
  7. 7.2 Tara Immuno-Oncology Therapeutics LLC
  8. 7.2.1 Tara Immuno-Oncology Therapeutics LLC Company Information
  9. 7.2.2 Tara Immuno-Oncology Therapeutics LLC Business Overview
  10. 7.2.3 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio
  12. 7.2.5 Tara Immuno-Oncology Therapeutics LLC Recent Developments
  13. 7.3 Stemline Therapeutics, Inc.
  14. 7.3.1 Stemline Therapeutics, Inc. Company Information
  15. 7.3.2 Stemline Therapeutics, Inc. Business Overview
  16. 7.3.3 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio
  18. 7.3.5 Stemline Therapeutics, Inc. Recent Developments
  19. 7.4 SK Biopharmaceuticals Co., Ltd.
  20. 7.4.1 SK Biopharmaceuticals Co., Ltd. Company Information
  21. 7.4.2 SK Biopharmaceuticals Co., Ltd. Business Overview
  22. 7.4.3 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
  24. 7.4.5 SK Biopharmaceuticals Co., Ltd. Recent Developments
  25. 7.5 Shenzen SiBiono GeneTech Co., Ltd.
  26. 7.5.1 Shenzen SiBiono GeneTech Co., Ltd. Company Information
  27. 7.5.2 Shenzen SiBiono GeneTech Co., Ltd. Business Overview
  28. 7.5.3 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
  30. 7.5.5 Shenzen SiBiono GeneTech Co., Ltd. Recent Developments
  31. 7.6 Quark Pharmaceuticals, Inc.
  32. 7.6.1 Quark Pharmaceuticals, Inc. Company Information
  33. 7.6.2 Quark Pharmaceuticals, Inc. Business Overview
  34. 7.6.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio
  36. 7.6.5 Quark Pharmaceuticals, Inc. Recent Developments
  37. 7.7 PCI Biotech Holding ASA
  38. 7.7.1 PCI Biotech Holding ASA Company Information
  39. 7.7.2 PCI Biotech Holding ASA Business Overview
  40. 7.7.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio
  42. 7.7.5 PCI Biotech Holding ASA Recent Developments
  43. 7.8 OSE Pharma SA
  44. 7.8.1 OSE Pharma SA Company Information
  45. 7.8.2 OSE Pharma SA Business Overview
  46. 7.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio
  48. 7.8.5 OSE Pharma SA Recent Developments
  49. 7.9 ORCA Therapeutics B.V.
  50. 7.9.1 ORCA Therapeutics B.V. Company Information
  51. 7.9.2 ORCA Therapeutics B.V. Business Overview
  52. 7.9.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio
  54. 7.9.5 ORCA Therapeutics B.V. Recent Developments
  55. 7.10 Eleos Inc.
  56. 7.10.1 Eleos Inc. Company Information
  57. 7.10.2 Eleos Inc. Business Overview
  58. 7.10.3 Eleos Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio
  60. 7.10.5 Eleos Inc. Recent Developments
  61. 7.11 Critical Outcome Technologies Inc.
  62. 7.11.1 Critical Outcome Technologies Inc. Company Information
  63. 7.11.2 Critical Outcome Technologies Inc. Business Overview
  64. 7.11.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio
  66. 7.11.5 Critical Outcome Technologies Inc. Recent Developments
  67. 7.12 Cellceutix Corporation
  68. 7.12.1 Cellceutix Corporation Company Information
  69. 7.12.2 Cellceutix Corporation Business Overview
  70. 7.12.3 Cellceutix Corporation Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio
  72. 7.12.5 Cellceutix Corporation Recent Developments
  73. 7.13 Aprea AB
  74. 7.13.1 Aprea AB Company Information
  75. 7.13.2 Aprea AB Business Overview
  76. 7.13.3 Aprea AB Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Aprea AB Cellular Tumor Antigen p53 Product Portfolio
  78. 7.13.5 Aprea AB Recent Developments
  79. 7.14 American Gene Technologies International Inc.
  80. 7.14.1 American Gene Technologies International Inc. Company Information
  81. 7.14.2 American Gene Technologies International Inc. Business Overview
  82. 7.14.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio
  84. 7.14.5 American Gene Technologies International Inc. Recent Developments
  85. 7.15 Advaxis, Inc.
  86. 7.15.1 Advaxis, Inc. Company Information
  87. 7.15.2 Advaxis, Inc. Business Overview
  88. 7.15.3 Advaxis, Inc. Cellular Tumor Antigen p53 Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio
  90. 7.15.5 Advaxis, Inc. Recent Developments
8 North America
  1. 8.1 North America Cellular Tumor Antigen p53 Market Size by Type
  2. 8.1.1 North America Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  3. 8.1.2 North America Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  4. 8.1.3 North America Cellular Tumor Antigen p53 Price by Type (2021-2032)
  5. 8.2 North America Cellular Tumor Antigen p53 Market Size by Application
  6. 8.2.1 North America Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  7. 8.2.2 North America Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  8. 8.2.3 North America Cellular Tumor Antigen p53 Price by Application (2021-2032)
  9. 8.3 North America Cellular Tumor Antigen p53 Market Size by Country
  10. 8.3.1 North America Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cellular Tumor Antigen p53 Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Cellular Tumor Antigen p53 Market Size by Type
  2. 9.1.1 Europe Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  4. 9.1.3 Europe Cellular Tumor Antigen p53 Price by Type (2021-2032)
  5. 9.2 Europe Cellular Tumor Antigen p53 Market Size by Application
  6. 9.2.1 Europe Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  8. 9.2.3 Europe Cellular Tumor Antigen p53 Price by Application (2021-2032)
  9. 9.3 Europe Cellular Tumor Antigen p53 Market Size by Country
  10. 9.3.1 Europe Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cellular Tumor Antigen p53 Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Cellular Tumor Antigen p53 Market Size by Type
  2. 10.1.1 China Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  3. 10.1.2 China Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  4. 10.1.3 China Cellular Tumor Antigen p53 Price by Type (2021-2032)
  5. 10.2 China Cellular Tumor Antigen p53 Market Size by Application
  6. 10.2.1 China Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  7. 10.2.2 China Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  8. 10.2.3 China Cellular Tumor Antigen p53 Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cellular Tumor Antigen p53 Market Size by Type
  2. 11.1.1 Asia Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  4. 11.1.3 Asia Cellular Tumor Antigen p53 Price by Type (2021-2032)
  5. 11.2 Asia Cellular Tumor Antigen p53 Market Size by Application
  6. 11.2.1 Asia Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  8. 11.2.3 Asia Cellular Tumor Antigen p53 Price by Application (2021-2032)
  9. 11.3 Asia Cellular Tumor Antigen p53 Market Size by Country
  10. 11.3.1 Asia Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cellular Tumor Antigen p53 Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cellular Tumor Antigen p53 Market Size by Type
  2. 12.1.1 SAMEA Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cellular Tumor Antigen p53 Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cellular Tumor Antigen p53 Price by Type (2021-2032)
  5. 12.2 SAMEA Cellular Tumor Antigen p53 Market Size by Application
  6. 12.2.1 SAMEA Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cellular Tumor Antigen p53 Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cellular Tumor Antigen p53 Price by Application (2021-2032)
  9. 12.3 SAMEA Cellular Tumor Antigen p53 Market Size by Country
  10. 12.3.1 SAMEA Cellular Tumor Antigen p53 Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cellular Tumor Antigen p53 Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cellular Tumor Antigen p53 Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cellular Tumor Antigen p53 Value Chain Analysis
  2. 13.1.1 Cellular Tumor Antigen p53 Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cellular Tumor Antigen p53 Production Mode & Process
  6. 13.2 Cellular Tumor Antigen p53 Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cellular Tumor Antigen p53 Distributors
  9. 13.2.3 Cellular Tumor Antigen p53 Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst